| __timestamp | Protagonist Therapeutics, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 1860000 | 91733000 |
| Thursday, January 1, 2015 | 2963000 | 87644000 |
| Friday, January 1, 2016 | 6961000 | 92365000 |
| Sunday, January 1, 2017 | 11779000 | 85656000 |
| Monday, January 1, 2018 | 13697000 | 88196000 |
| Tuesday, January 1, 2019 | 15749000 | 89971000 |
| Wednesday, January 1, 2020 | 18638000 | 93413000 |
| Friday, January 1, 2021 | 27196000 | 91355000 |
| Saturday, January 1, 2022 | 31739000 | 113676000 |
| Sunday, January 1, 2023 | 33491000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, effective cost management is crucial. Protagonist Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd. offer a compelling study in contrasts. Over the past decade, Protagonist Therapeutics has seen its Selling, General, and Administrative (SG&A) expenses grow by nearly 1,700%, from a modest $1.86 million in 2014 to a substantial $33.49 million in 2023. This reflects the company's aggressive expansion and investment in operational capabilities.
Conversely, Taro Pharmaceutical Industries Ltd. has maintained a more stable trajectory, with SG&A expenses increasing by approximately 116% over the same period, reaching $198.37 million in 2023. This steadier growth suggests a focus on efficiency and cost control. The data for 2024 is incomplete, highlighting the dynamic nature of financial forecasting. As these companies continue to evolve, their SG&A strategies will be pivotal in shaping their competitive edge.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Protagonist Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing argenx SE and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Taro Pharmaceutical Industries Ltd.
SG&A Efficiency Analysis: Comparing Opthea Limited and Protagonist Therapeutics, Inc.
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends